Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca and Lilly.

For further information concerning Lilly grant funding visit

Medical Crossfire®: Navigating Frontline Decision-Making in EGFR-Mutant Lung Cancer: The Experts Assess Application of the Evidence

Release Date: October 30, 2020
Expiration Date: October 30, 2021

Activity Overview

Treatment options continue to expand for patients with non–small lung cancer (NSCLC), especially in the context of targetable molecular alterations. There are now multiple options for first-line treatment of advanced EGFR-mutated NSCLC, including monotherapy and combination strategies, and many ongoing clinical trials that may expand these options in the near future. In this Medical Crossfire®, the faculty will defend their positions on which data are the most promising for optimal frontline treatment of NSCLC. These data will then be integrated into real-world clinical scenarios to aid in applying the information to the care of your patients.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Lilly.

For further information concerning Lilly grant funding visit

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is intended for medical oncologists and other health care professionals interested in the latest advances in the treatment of patients with NSCLC. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with NSCLC are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the rationale for combination therapies in the setting of advanced NSCLC and EGFR mutations
  • Assess key clinical data related to initial therapy for patients with EGFR mutation-positive NSCLC
  • Evaluate the application of current and emerging molecular testing approaches to optimize therapy for patients with metastatic NSCLC
  • Describe therapeutic approaches for patients with EGFR mutation-positive NSCLC and CNS involvement and/or therapy-related adverse events

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Heather A. Wakelee, MD
Heather A. Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Disclosures: Grant/Research Support: Arrys Therapeutics, Novartis Pharmaceuticals, Merck & Co., Bristol Myers Squibb, Exelixis, Pfizer, Eli Lilly & Company; Consultant: AstraZeneca, Mirati Therapeutics, Helsinn Therapeutics; Other Support: Steering Committee Participation/Unpaid Advisor: Genentech/Hoffman La-Roche, Merck & Co., Cellworks.


Benjamin P. Levy, MD
Benjamin P. Levy, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Clinical Director, Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca, Pfizer, Merck & Co., Eli Lilly & Company, Novartis Pharmaceuticals, Guardant 360, Takeda

Suresh S. Ramalingam, MD, FACP, FASCO
Suresh S. Ramalingam, MD, FACP, FASCO
Roberto C. Goizueta Distinguished Chair for Cancer Research
Deputy Director, Winship Cancer Institute of Emory University
Emory University School of Medicine
Atlanta, GA

Disclosures: Grant Research Support: Tesaro, Merck & Co., AstraZeneca, Advaxis, Bristol Myers Squibb, Amgen; Consultant: Amgen, AbbVie, Bristol Myers Squibb, Genentech, Merck & Co., AstraZeneca, Takeda, GlaxoSmithKline, Eisai.

Gregory Riely, MD, PhD
Gregory Riely, MD, PhD
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: (To institution) Merck & Co., Inc., Mirati Therapeutics, Novartis, Pfizer, Roche

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By